Anti‐IL‐5 mAb (mepolizumab) vs placebo: Durable remission
Mepolizumab may leads to higher durable remission within the first 24 weeks sustained until week 52 compared with placebo (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Mepolizumab vs placebo Durable remission within the first 24 weeks sustained until week 52 · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis Mepolizumab may leads to higher durable remission within the first 24 weeks sustained until week 52 compared with placebo (low certainty). Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane Headline outcomes only | RR 13 [1.75, 96.33] | Not reported | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.